APO RESEARCH · REPORT
PD-L1 Biomarker Testing
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Product & engineering
Understand the product.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
Selected research
Industry Growth & Trends
Global PD-L1 Biomarker Testing Industry Growth and Trends Forecast to 2032
Market perspective
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
Read the full market overview
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
According to APO Research, the global PD-L1 Biomarker Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
This report provides a structured, data-driven view of the global PD-L1 Biomarker Testing market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The PD-L1 Biomarker Testing market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PD-L1 Biomarker Testing market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PD-L1 Biomarker Testing.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global PD-L1 Biomarker Testing market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
PD-L1 Biomarker Testing Market by Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
PD-L1 Biomarker Testing Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
PD-L1 Biomarker Testing Segment by Application
Hospital
Diagnostic Center
Others
PD-L1 Biomarker Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Biomarker Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Biomarker Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Biomarker Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of PD-L1 Biomarker Testing companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- PD-L1 (22C3)
- PD-L1(28-8)
- PD-L1 (SP142)
- PD-L1 (SP263)
- Other
Applications
- Hospital
- Diagnostic Center
- Others
Companies covered
- Agilent Technologies
- Roche
- Merck
- Bristol-Myers Squibb
- AstraZeneca
- Ono Pharmaceutical
- Regeneron
- Innovent
- Hengrui Medicine
- Junshi Biosciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global PD-L1 Biomarker Testing Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global PD-L1 Biomarker Testing Market Size by Region (2021-2032)
- 1.4.1 Global PD-L1 Biomarker Testing Market Size by Region (2021-2026)
- 1.4.2 Global PD-L1 Biomarker Testing Market Size by Region (2027-2032)
- 1.5 Key Regions PD-L1 Biomarker Testing Market Size (2021-2032)
- 1.5.1 North America PD-L1 Biomarker Testing Market Size Growth Rate (2021-2032)
- 1.5.2 Europe PD-L1 Biomarker Testing Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific PD-L1 Biomarker Testing Market Size Growth Rate (2021-2032)
- 1.5.4 South America PD-L1 Biomarker Testing Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa PD-L1 Biomarker Testing Market Size Growth Rate (2021-2032)
2 PD-L1 Biomarker Testing Market by Type
- 2.1 Type Introduction
- 2.1.1 PD-L1 (22C3)
- 2.1.2 PD-L1(28-8)
- 2.1.3 PD-L1 (SP142)
- 2.1.4 PD-L1 (SP263)
- 2.1.5 Other
- 2.2 Global PD-L1 Biomarker Testing Market Size by Type
- 2.2.1 Global PD-L1 Biomarker Testing Market Size Overview by Type (2021-2032)
- 2.2.2 Global PD-L1 Biomarker Testing Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global PD-L1 Biomarker Testing Market Size Forecasted by Type (2027-2032)
- 2.3 Global PD-L1 Biomarker Testing Market Size by Regions
- 2.3.1 North America PD-L1 Biomarker Testing Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe PD-L1 Biomarker Testing Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific PD-L1 Biomarker Testing Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America PD-L1 Biomarker Testing Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa PD-L1 Biomarker Testing Market Size Breakdown by Type (2021-2026)
3 PD-L1 Biomarker Testing Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Diagnostic Center
- 3.1.3 Others
- 3.2 Global PD-L1 Biomarker Testing Market Size by Application
- 3.2.1 Global PD-L1 Biomarker Testing Market Size Overview by Application (2021-2032)
- 3.2.2 Global PD-L1 Biomarker Testing Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global PD-L1 Biomarker Testing Market Size Forecasted by Application (2027-2032)
- 3.3 Global PD-L1 Biomarker Testing Market Size by Regions
- 3.3.1 North America PD-L1 Biomarker Testing Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe PD-L1 Biomarker Testing Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific PD-L1 Biomarker Testing Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America PD-L1 Biomarker Testing Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa PD-L1 Biomarker Testing Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 PD-L1 Biomarker Testing Industry Trends
- 4.2 PD-L1 Biomarker Testing Industry Drivers
- 4.3 PD-L1 Biomarker Testing Industry Opportunities and Challenges
- 4.4 PD-L1 Biomarker Testing Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by PD-L1 Biomarker Testing Revenue (2021-2026)
- 5.2 Global PD-L1 Biomarker Testing Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global PD-L1 Biomarker Testing Key Company Headquarters & Area Served
- 5.4 Global PD-L1 Biomarker Testing Company, Product Type & Application
- 5.5 Global PD-L1 Biomarker Testing Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global PD-L1 Biomarker Testing Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 PD-L1 Biomarker Testing Players Market Share by Revenue in 2025
- 5.6.3 2025 PD-L1 Biomarker Testing Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Agilent Technologies
- 6.1.1 Agilent Technologies Company Information
- 6.1.2 Agilent Technologies Business Overview
- 6.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
- 6.1.5 Agilent Technologies Recent Developments
- 6.2 Roche
- 6.2.1 Roche Company Information
- 6.2.2 Roche Business Overview
- 6.2.3 Roche PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Roche PD-L1 Biomarker Testing Product Portfolio
- 6.2.5 Roche Recent Developments
- 6.3 Merck
- 6.3.1 Merck Company Information
- 6.3.2 Merck Business Overview
- 6.3.3 Merck PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck PD-L1 Biomarker Testing Product Portfolio
- 6.3.5 Merck Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 AstraZeneca
- 6.5.1 AstraZeneca Company Information
- 6.5.2 AstraZeneca Business Overview
- 6.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
- 6.5.5 AstraZeneca Recent Developments
- 6.6 Ono Pharmaceutical
- 6.6.1 Ono Pharmaceutical Company Information
- 6.6.2 Ono Pharmaceutical Business Overview
- 6.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
- 6.6.5 Ono Pharmaceutical Recent Developments
- 6.7 Regeneron
- 6.7.1 Regeneron Company Information
- 6.7.2 Regeneron Business Overview
- 6.7.3 Regeneron PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Regeneron PD-L1 Biomarker Testing Product Portfolio
- 6.7.5 Regeneron Recent Developments
- 6.8 Innovent
- 6.8.1 Innovent Company Information
- 6.8.2 Innovent Business Overview
- 6.8.3 Innovent PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Innovent PD-L1 Biomarker Testing Product Portfolio
- 6.8.5 Innovent Recent Developments
- 6.9 Hengrui Medicine
- 6.9.1 Hengrui Medicine Company Information
- 6.9.2 Hengrui Medicine Business Overview
- 6.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
- 6.9.5 Hengrui Medicine Recent Developments
- 6.10 Junshi Biosciences
- 6.10.1 Junshi Biosciences Company Information
- 6.10.2 Junshi Biosciences Business Overview
- 6.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
- 6.10.5 Junshi Biosciences Recent Developments
7 North America
- 7.1 North America PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 7.3 North America PD-L1 Biomarker Testing Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 8.3 Europe PD-L1 Biomarker Testing Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 9.3 Asia-Pacific PD-L1 Biomarker Testing Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 10.3 South America PD-L1 Biomarker Testing Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 11.3 Middle East & Africa PD-L1 Biomarker Testing Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst